Management of Functional Pancreatic Neuroendocrine Neoplasms

Curr Treat Options Oncol. 2023 Jul;24(7):725-741. doi: 10.1007/s11864-023-01085-0. Epub 2023 Apr 27.

Abstract

Functional pancreatic neuroendocrine neoplasms (pNENs) are rare and heterogeneous diseases in terms of both clinical and pathological aspects. These tumors secrete hormones or peptides, which may cause a wide variety of symptoms related to a clinical syndrome. The management of functional pNENs is still challenging for clinicians due to the need to control both tumor growth and specific symptoms. Surgery remains the cornerstone in the management of local disease because it can definitively cure the patient. However, when the disease is not resectable, a broad spectrum of therapeutic options, including locoregional therapy, somatostatin analogs (SSAs), targeted therapies, peptide-receptor radionuclide therapy (PRRT), and chemotherapy, are available. The present review summarizes the main key issues regarding the clinical management of these tumors, providing a specific highlight on their therapeutic approach.

Keywords: Gastrinoma; Insulinoma; Neuroendocrine tumors; Somatostatin analogs; Treatment.

Publication types

  • Review

MeSH terms

  • Humans
  • Intestinal Neoplasms* / drug therapy
  • Neuroendocrine Tumors* / diagnosis
  • Neuroendocrine Tumors* / etiology
  • Neuroendocrine Tumors* / therapy
  • Pancreatic Neoplasms* / diagnosis
  • Pancreatic Neoplasms* / etiology
  • Pancreatic Neoplasms* / therapy
  • Receptors, Somatostatin
  • Somatostatin / therapeutic use
  • Stomach Neoplasms* / drug therapy

Substances

  • Somatostatin
  • Receptors, Somatostatin